急诊集束化管理对老年急性心衰患者30天离院生存天数的影响:ELISABETH随机临床试验
该阶梯楔形整群随机试验在法国15个急诊科纳入503例75岁及以上急性心衰患者,评估早期指南推荐集束化治疗(静脉硝酸酯、诱因管理、中等剂量静脉利尿剂)对30天离院生存天数的影响。结果显示干预组与常规组主要终点无统计学显著差异,30天死亡率、心血管死亡、非计划再入院等次要终点亦无显著差异。
要点
- 早期集束化治疗未显著改善老年急性心衰患者30天离院生存天数。
- 干预组静脉硝酸酯用量及诱因治疗比例显著高于常规组。
- 30天死亡率、心血管死亡、再入院及肾损伤均无显著差异。
核心结论
- 在急诊老年急性心衰患者中,指南推荐的综合集束化治疗与常规治疗相比,30天离院生存天数无统计学显著差异。
研究设计与样本
- 阶梯楔形整群随机试验,在法国15个急诊科纳入503例75岁及以上急性心衰患者,2018年12月至2019年9月入组并随访30天。
- 干预组200例接受早期静脉硝酸酯团注、诱因管理及中等剂量静脉利尿剂,对照组303例由急诊医师自主决定治疗。
主要发现
- 干预组前4小时静脉硝酸酯中位剂量27.0 mg(IQR 9-54),对照组4.0 mg(IQR 2.0-6.0),校正差值23.8 mg(95%CI 13.5-34.1)。
- 干预组诱因治疗比例58.8%,对照组31.9%,校正差值31.1%(95%CI 14.3%-47.9%)。
- 30天离院生存天数两组中位均为19天(IQR 0-24),校正差值-1.9天(95%CI -6.6至2.8),校正比值0.88(95%CI 0.64-1.21)。
- 30天全因死亡率干预组8.0% vs 对照组9.7%(校正差值4.1%,95%CI -17.2%至25.3%),心血管死亡5.0% vs 7.4%(校正差值2.1%,95%CI -15.5%至19.8%)。
- 非计划再入院14.3% vs 15.7%(校正差值-1.3%,95%CI -26.3%至23.7%),中位住院天数两组均为8天(校正差值2.5,95%CI -0.9至5.8),肾损伤两组均为1%。
临床怎么用
- 急诊对老年急性心衰患者实施指南推荐集束化治疗未显示短期预后获益,临床决策仍需个体化。
局限性
- 研究仅纳入法国15个急诊科75岁及以上患者,结论外推需谨慎。
- 干预组与对照组样本量不均衡(200例 vs 303例),可能影响比较效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical guidelines for the early management of acute heart failure in the emergency department (ED) setting are based on only moderate levels of evidence, with subsequent low adherence to these guidelines. OBJECTIVE: To test the effect of an early guideline-recommended care bundle on short-term prognosis in older patients with acute heart failure in the ED. DESIGN, SETTING, AND PARTICIPANTS: Stepped-wedge cluster randomized trial in 15 EDs in France of 503 patients 75 years and older with a diagnosis of acute heart failure in the ED from December 2018 to September 2019 and followed up for 30 days until October 2019. INTERVENTIONS: A care bundle that included early intravenous nitrate boluses; management of precipitating factors, such as acute coronary syndrome, infection, or atrial fibrillation; and moderate dose of intravenous diuretics (n = 200). In the control group, patient care was left to the discretion of the treating emergency physician (n = 303). Each center was randomized to the order in which they switched to the "intervention period." After the initial 4-week control period for all centers, 1 center entered in the intervention period every 2 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the number of days alive and out of hospital at 30 days. Secondary outcomes included 30-day all-cause mortality, 30-day cardiovascular mortality, unscheduled readmission, length of hospital stay, and kidney impairment. RESULTS: Among 503 patients who were randomized (median age, 87 years; 298 [59%] women), 502 were analyzed. In the intervention group, patients received a median (interquartile range) of 27.0 (9-54) mg of intravenous nitrates in the first 4 hours vs 4.0 (2.0-6.0) mg in the control group (adjusted difference, 23.8 [95% CI, 13.5-34.1]). There was a significantly higher percentage of patients in the intervention group treated for their precipitating factors than in the control group (58.8% vs 31.9%; adjusted difference, 31.1% [95% CI, 14.3%-47.9%]). There was no statistically significant difference in the primary end point of the number of days alive and out of hospital at 30 days (median [interquartile range], 19 [0- 24] d in both groups; adjusted difference, -1.9 [95% CI, -6.6 to 2.8]; adjusted ratio, 0.88 [95% CI, 0.64-1.21]). At 30 days, there was no significant difference between the intervention and control groups in mortality (8.0% vs 9.7%; adjusted difference, 4.1% [95% CI, -17.2% to 25.3%]), cardiovascular mortality (5.0% vs 7.4%; adjusted difference, 2.1% [95% CI, -15.5% to 19.8%]), unscheduled readmission (14.3% vs 15.7%; adjusted difference, -1.3% [95% CI, -26.3% to 23.7%]), median length of hospital stay (8 d in both groups; adjusted difference, 2.5 [95% CI, -0.9 to 5.8]), and kidney impairment (1% in both groups). CONCLUSIONS AND RELEVANCE: Among older patients with acute heart failure, use of a guideline-based comprehensive care bundle in the ED compared with usual care did not result in a statistically significant difference in the number of days alive and out of the hospital at 30 days. Further research is needed to identify effective treatments for acute heart failure in older patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03683212.
引用
- Freund Y, Cachanado M, Delannoy Q, et al. Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial. JAMA. 2020. PMID: 33201202. doi:10.1001/jama.2020.19378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。